Related references
Note: Only part of the references are listed.Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience
Takeo Fujii et al.
INVESTIGATIONAL NEW DRUGS (2018)
Cyanidin-3-o-beta-Glucoside Induces Megakaryocyte Apoptosis via PI3K/Akt- and MAPKs-Mediated Inhibition of NF-kappa B Signalling
Fuli Ya et al.
THROMBOSIS AND HAEMOSTASIS (2018)
The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL
Ian W. Flinn et al.
BLOOD (2018)
Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma
P. Penttila et al.
EUROPEAN JOURNAL OF CANCER (2017)
Regulation of mitochondrial biogenesis in erythropoiesis by mTORC1-mediated protein translation
Xin Liu et al.
NATURE CELL BIOLOGY (2017)
The PI3K Pathway in Human Disease
David A. Fruman et al.
CELL (2017)
Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy
H. S. Rugo et al.
ANNALS OF ONCOLOGY (2016)
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity
Benjamin L. Lampson et al.
BLOOD (2016)
A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study)
Vicky Makker et al.
CANCER (2016)
The anti-apoptotic Bcl-2 family protein A1/Bfl-1 regulates neutrophil survival and homeostasis and is controlled via PI3K and JAK/STAT signaling
J. Vier et al.
CELL DEATH & DISEASE (2016)
AKT/GSK3β signaling pathway is critically involved in human pluripotent stem cell survival
Leonardo Romorini et al.
SCIENTIFIC REPORTS (2016)
The Roles of mTOR Complexes in Lipid Metabolism
Alexandre Caron et al.
ANNUAL REVIEW OF NUTRITION, VOL 35 (2015)
Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials
E. Geuna et al.
BRITISH JOURNAL OF CANCER (2015)
Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma
Jennifer R. Brown et al.
CLINICAL CANCER RESEARCH (2015)
First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer (vol 20, pg 5908, 2014)
S. Blagden et al.
CLINICAL CANCER RESEARCH (2015)
The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab
Naifa L. Busaidy et al.
ONCOLOGIST (2015)
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
Jennifer R. Brown et al.
BLOOD (2014)
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma
Ian W. Flinn et al.
BLOOD (2014)
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
Geoffrey I. Shapiro et al.
CLINICAL CANCER RESEARCH (2014)
Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms
Ignacio Duran et al.
EXPERT OPINION ON DRUG SAFETY (2014)
Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer
Daliah Tsoref et al.
GYNECOLOGIC ONCOLOGY (2014)
Computer-Aided Targeting of the PI3K/Akt/mTOR Pathway: Toxicity Reduction and Therapeutic Opportunities
Tan Li et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2014)
Tilting the Balance of Dose Modification for Oral Anticancer Drugs?
Philippe L. Bedard et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Incidence of Mucositis in Patients Treated With Temsirolimus-Based Regimens and Correlation to Treatment Response
Xiaochun Liu et al.
ONCOLOGIST (2014)
A critical role for mTORC1 in erythropoiesis and anemia
Zachary A. Knight et al.
ELIFE (2014)
A Central Role for mTOR in Lipid Homeostasis
Dudley W. Lamming et al.
CELL METABOLISM (2013)
PI3K-δ and PI3K-γ Inhibition by IPI-145 Abrogates Immune Responses and Suppresses Activity in Autoimmune and Inflammatory Disease Models
David G. Winkler et al.
CHEMISTRY & BIOLOGY (2013)
Metabolic complications with the use of mTOR inhibitors for cancer therapy: A systematic review and meta-analysis
Shanthi Sivendran et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
Ningshu Liu et al.
MOLECULAR CANCER THERAPEUTICS (2013)
A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients
Fabiana Martins et al.
ORAL ONCOLOGY (2013)
Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors
B. Markman et al.
ANNALS OF ONCOLOGY (2012)
Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors
Yoshitaka Seki et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2012)
The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: A systematic review of the literature and meta-analysis
Cristina Gomez-Fernandez et al.
EUROPEAN JOURNAL OF CANCER (2012)
Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic findings and correlation with clinical outcome
Donnette A. Dabydeen et al.
EUROPEAN JOURNAL OF CANCER (2012)
PI3K/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis
Simon M. Schultze et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2012)
A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma
Christoph Renner et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Infection with Anaplasma phagocytophilum Activates the Phosphatidylinositol 3-Kinase/Akt and NF-κB Survival Pathways in Neutrophil Granulocytes
Arup Sarkar et al.
INFECTION AND IMMUNITY (2012)
Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway
Naifa L. Busaidy et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia
E. J. Gallagher et al.
ONCOGENE (2012)
Functional Redundancy of Class I Phosphoinositide 3-Kinase (PI3K) Isoforms in Signaling Growth Factor-Mediated Human Neutrophil Survival
Jatinder K. Juss et al.
PLOS ONE (2012)
Phase 1/2 Study of Everolimus in Advanced Hepatocellular Carcinoma
Andrew X. Zhu et al.
CANCER (2011)
Cooperation between both Wnt/β-catenin and PTEN/PI3K/Akt signaling promotes primitive hematopoietic stem cell self-renewal and expansion
John M. Perry et al.
GENES & DEVELOPMENT (2011)
Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group
Amit M. Oza et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Clinical presentation and management of mTOR inhibitor-associated stomatitis
Marcio Augusto de Oliveira et al.
ORAL ONCOLOGY (2011)
Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma Final Results and Analysis of Prognostic Factors
Robert J. Motzer et al.
CANCER (2010)
Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer
Ahmad Tarhini et al.
CLINICAL CANCER RESEARCH (2010)
Chronic Rapamycin Treatment Causes Glucose Intolerance and Hyperlipidemia by Upregulating Hepatic Gluconeogenesis and Impairing Lipid Deposition in Adipose Tissue
Vanessa P. Houde et al.
DIABETES (2010)
Rtp801, a suppressor of mTOR signaling, is an essential mediator of cigarette smoke-induced pulmonary injury and emphysema
Toshinori Yoshida et al.
NATURE MEDICINE (2010)
Neutrophil spontaneous death is mediated by down-regulation of autocrine signaling through GPCR, PI3Kγ, ROS, and actin
Yuanfu Xu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Targeted deletion of tumor suppressor PTEN augments neutrophil function and enhances host defense in neutropenia-associated pneumonia
Yitang Li et al.
BLOOD (2009)
Comprehensive lung injury pathology induced by mTOR inhibitors
Guadalupe Aparicio et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2009)
Drug-Induced Thrombocytopenia An Updated Systematic Review, 2008
Karen K. Swisher et al.
DRUG SAFETY (2009)
Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163
Susan L. Ellard et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
PI3K/Akt activation is critical for early hepatic regeneration after partial hepatectomy
Lindsey N. Jackson et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2008)
Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features
J. Bellmunt et al.
ANNALS OF ONCOLOGY (2008)
PI3K/Akt/FOXO3a pathway contributes to thrombopoietin-induced proliferation of primary megakaryocytes in vitro and in vivo via modulation of p27Kip1
Takafumi Nakao et al.
CELL CYCLE (2008)
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies
David A. Rizzieri et al.
CLINICAL CANCER RESEARCH (2008)
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies
Monica M. Mita et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The role of phosphoinositide 3-kinase C2α in insulin signaling
Marco Falasca et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Life with a single isoform of Akt: Mice lacking Akt2 and Akt3 are viable but display impaired glucose homeostasis and growth deficiencies
Bettina Dummler et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Deactivation of phosphatidylinositol 3,4,5-trisphosphate/Akt signaling mediates neutrophil spontaneous death
Daocheng Zhu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Jeffrey A. Engelman et al.
NATURE REVIEWS GENETICS (2006)
A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling
Zachary A. Knight et al.
CELL (2006)
Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation
LC Foukas et al.
NATURE (2006)
A pharmacological map of the PI3-K family defines a role for p110 alpha in insulin signaling
Zachary A. Knight et al.
CELL (2006)
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer
S Chan et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer treatment group study
E Galanis et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
PI 3-kinase p110β:: a new target for antithrombotic therapy
SP Jackson et al.
NATURE MEDICINE (2005)
Chronic benign neutropenia diagnosed due to severe stomatitis: a case report
Yumiko Otsuka et al.
PEDIATRIC DENTAL JOURNAL (2005)
Selective role of PI3Kδ in neutrophil inflammatory responses
C Sadhu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Inhibition of the MAPK and PI3K pathways enhances UDCA-induced apoptosis in primary rodent hepatocytes
L Qiao et al.
HEPATOLOGY (2002)
Quantification of oral mucositis due to radiotherapy by determining viability and maturation of epithelial cells
MA Stokman et al.
JOURNAL OF ORAL PATHOLOGY & MEDICINE (2002)
Akt1/PKBα is required for normal growth but dispensable for maintenance of glucose homeostasis in mice
H Cho et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients.
E Morelon et al.
TRANSPLANTATION (2001)
A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts
AS MacDonald
TRANSPLANTATION (2001)
Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study
BD Kahan
LANCET (2000)
Share Paper
